Compare Amphastar Pharmaceuticals Inc (AMPH) vs Asana Inc. (ASAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Asana Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Asana Inc. trades at $9.24 (market cap $2.13B). The key difference: Asana Inc. is far larger — about 2.5× Amphastar Pharmaceuticals Inc's market cap, and Asana Inc. is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | ASAN | |
|---|---|---|
Market Cap | $863.95M | $2.13B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $15.19 |
52-Week Low | $16.87 | $5.46 |
Enterprise Value | $1.26B | $1.95B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Asana (ASAN) trades at $9.26, up 6.68% today, with a bullish technical signal from moving averages and a consensus price target of $10.33. Recent quarterly earnings have consistently beaten expectations, including Q1 2027 EPS of $0.10 versus $0.08 expected. Revenue growth is steady, reaching $724 million in 2025, but profitability remains negative with a net margin of -20.21%. The company is advancing its AI capabilities, highlighted by the StackAI acquisition announced on May 28, 2026.
The outlook is mixed: strong revenue growth and AI innovation support upside potential, but persistent losses and intense competition from Microsoft and Alphabet pose significant risks. Analyst sentiment is divided, with 42% buy ratings. Earnings momentum is key for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Asana Inc.
Asana Inc is a software company. The company provides a platform for work management that helps teams orchestrate work, from daily tasks to cross-functional strategic initiatives. It helps plan marketing campaigns, streamlines processes, manages sales, and manage product launches. Also, the company provides project management and workflow management solutions.
Read more on ASAN →
